EpiVax recently received $5.2 million in investments from the Defense Threat Reduction Agency (DTRA) for creating a new vaccine to prevent Q fever.
Mark Pozansky from the Vaccine and Immunotherapy Center (VIC) and Massachusetts General Hospital has collaborated with Annie De Groot from EpiVax to lead both academic and industry organizations in focusing on rapid vaccine development. These vaccines will be specifically dedicated to emerging infectious diseases.
The new VaxCelerate consortium has members from all around the world including Yale University in Connecticut, InnatOss Laboratories in the Netherlands, and Colorado State University. EpiVax will contribute immunoinformatics tools to help the collaborators create the vaccine.
In light of the slow response to 2009’s H1N1 flu outbreak, the United States federal government has made considerable investments for rapid vaccine manufacturing approaches. Vaccine companies see no slowing of investments as they race to create better vaccine development methods and treatments.
"EpiVax has worked hard to be at the forefront of the 'vaccines on demand' concept,” Sen. Jack Reed (D-RI), the ranking member of the Armed Services Committee, said. “Their selection as a partner in this project recognizes their leadership in terms of developing safer, more efficient vaccines and improving our national biodefense rapid response capabilities.”